hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in a Series A financing round, solely funded by Co-win Ventures. The proceeds will be used for talent recruitment, business expansion in the medical aesthetics and personal care field, and research and development of medical devices.
Company Background
TianShiWei positions itself as the first domestic company to file for marketing and launch a soluble microneedle product for the medical aesthetics field. The company’s platform-type transdermal drug delivery technology addresses the issues of low bioavailability of traditional transdermal patches and unsustainable administration of injections. It achieves efficient delivery of active ingredients and can be widely used in beauty personal care and serious medical fields due to its advantages such as being painless and minimally invasive, no first-pass effects, and improved bioavailability.-Fineline Info & Tech
